Health-related quality of life in a cohort of 1070 patients with hypoparathyroidism.

Abstract

Objective: To describe clinical and biochemical characteristics, including health-related quality of life (HRQoL), in patients with chronic hypoparathyroidism (cHypoPT) who were receiving conventional therapy (calcium and active vitamin D), and to compare baseline HRQoL between patients who subsequently received recombinant human parathyroid hormone (1-84) (rhPTH [1-84]) and those who did not.

Design: Cross-sectional analysis of data recorded at enrollment (baseline) from patients with cHypoPT in the PARADIGHM registry before May 31, 2022.

Methods: Eligible patients were aged ≥18 years and receiving conventional therapy at enrollment. Health-related quality of life was measured using the 36-Item Short-Form Health Survey version 2 (SF-36v2), Work Productivity and Activity Impairment Specific Health Problem (WPAI:SHP) questionnaire, and the Hypoparathyroidism Symptom Diary (HypoPT-SD).

Results: Eligible patients (N = 1070) were mostly female (80.7%) and White (86.0%). Surgery was the most common cause of cHypoPT (82.2%). Mean serum albumin-adjusted calcium, phosphate, and calcium-phosphate product levels were within the target ranges. Mean (standard deviation [SD]) SF-36v2 physical and mental component scores were 46.3 (10.2) and 47.6 (11.5), respectively (normative scores: 50). Patients who went on to receive rhPTH (1-84) (n = 102) had significantly worse baseline HRQoL scores than patients in the conventional therapy group (n = 968) for all SF-36v2 and HypoPT-SD parameters and most WPAI parameters. There were no meaningful differences in biochemical parameters between the groups.

Conclusions: Thirty-six-Item Short-Form Health Survey version 2 scores in patients with cHypoPT were lower than the normalized values reported previously for the US population. Patients who were subsequently prescribed rhPTH (1-84) had worse baseline HRQoL scores than those in the conventional therapy group.